213Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience

Decay data measurements on 213Bi using recoil atoms

(2013) M. Marouli et al.   APPLIED RADIATION AND ISOTOPES

Half-lives of 221Fr, 217At, 213Bi, 213Po and 209Pb from the 225Ac decay series

(2013) G. Suliman et al.   APPLIED RADIATION AND ISOTOPES

90Yttrium-Ibritumomab Tiuxetan Consolidation of First Remission in Advanced-Stage Follicular Non-Hodgkin Lymphoma: Updated Results After a Median Follow-Up of 7.3 Years From the International, Randomized, Phase III First-Line Indolent Trial

(2013) Franck Morschhauser et al.   JOURNAL OF CLINICAL ONCOLOGY

Long-Term Hematotoxicity After Peptide Receptor Radionuclide Therapy with 177Lu-Octreotate

(2013) A. Sabet et al.   JOURNAL OF NUCLEAR MEDICINE

Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer

(2013) C. Parker et al.   NEW ENGLAND JOURNAL OF MEDICINE

Measurement of the 225Ac half-life

(2012) S. Pommé et al.   APPLIED RADIATION AND ISOTOPES

225Ac and 223Ra production via 800MeV proton irradiation of natural thorium targets

(2012) J.W. Weidner et al.   APPLIED RADIATION AND ISOTOPES

FOLFIRI regimen: an effective second-line chemotherapy after failure of etoposide–platinum combination in patients with neuroendocrine carcinomas grade 3

(2012) O Hentic et al.   ENDOCRINE-RELATED CANCER

Comparison of neuroendocrine tumor detection and characterization using DOTATOC-PET in correlation with contrast enhanced CT and delayed contrast enhanced MRI

(2012) F.L. Giesel et al.   EUROPEAN JOURNAL OF RADIOLOGY

Alpha- versus Beta-Particle Radiopeptide Therapy in a Human Prostate Cancer Model (213Bi-DOTA-PESIN and 213Bi-AMBA versus177Lu-DOTA-PESIN)

(2011) D. Wild et al.   CANCER RESEARCH

Hepatic arterial infusion enhances DOTATOC radiopeptide therapy in patients with neuroendocrine liver metastases

(2011) Clemens Kratochwil et al.   ENDOCRINE-RELATED CANCER

Clinical results of radionuclide therapy of neuroendocrine tumours with 90Y-DOTATATE and tandem 90Y/177Lu-DOTATATE: which is a better therapy option?

(2011) Jolanta Kunikowska et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Intraindividual Comparison of Selective Arterial versus Venous 68Ga-DOTATOC PET/CT in Patients with Gastroenteropancreatic Neuroendocrine Tumors

(2010) C. Kratochwil et al.   CLINICAL CANCER RESEARCH

MIRD Pamphlet No. 22 (Abridged): Radiobiology and Dosimetry of  -Particle Emitters for Targeted Radionuclide Therapy

(2010) G. Sgouros et al.   JOURNAL OF NUCLEAR MEDICINE

Effects of therapy with [177Lu-DOTA0,Tyr3]octreotate on endocrine function

(2009) Jaap J. M. Teunissen et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Preclinical Evaluation of the  -Particle Generator Nuclide 225Ac for Somatostatin Receptor Radiotherapy of Neuroendocrine Tumors

(2008) M. Miederer et al.   CLINICAL CANCER RESEARCH

Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors

(2008) Lisa Bodei et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Treatment With the Radiolabeled Somatostatin Analog [177Lu-DOTA0,Tyr3]Octreotate: Toxicity, Efficacy, and Survival

(2008) Dik J. Kwekkeboom et al.   JOURNAL OF CLINICAL ONCOLOGY

Gastroenteropancreatic neuroendocrine tumours

(2008) Irvin M Modlin et al.   LANCET ONCOLOGY

Increased risk of myeloid leukaemia in patients with ankylosing spondylitis following treatment with radium-224

(2008) R. R. Wick et al.   RHEUMATOLOGY